Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience

References

• Turner R Cull C Holman R United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus Ann Intern Med 1996 124 1 Pt 2 136 145 8554206
   PubMed Web of Science ®Google Scholar
• Stettler C Allemann S Jüni P Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials Am Heart J 2006 152 1 27 38 16824829
   PubMed Web of Science ®Google Scholar
• Alvarez Guisasola F Tofé Povedano S Krishnarajah G Lyu R Mavros P Yin D Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study Diabetes Obes Metab 2008 10 Suppl 1 25 32 18435671
   PubMed Web of Science ®Google Scholar
• Weber KK Lohmann T Busch K Donati-Hirsch I Riel R High frequency of unrecognized hypoglycaemias in patients with type 2 diabetes is discovered by continuous glucose monitoring Exp Clin Endocrinol Diabetes 2007 115 8 491 494 17853331
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB for American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 6 1364 1379 22517736
   PubMed Web of Science ®Google Scholar
• Ahrén B GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors Curr Diab Rep 2007 7 5 340 347 18173966
   PubMedGoogle Scholar
• Mikhail N Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes Expert Opin Investig Drugs 2008 17 6 845 853
   PubMed Web of Science ®Google Scholar
• Scott LJ Exenatide extended-release: a review of its use in type 2 diabetes mellitus Drugs 2012 72 12 1679 1707 22867046
   PubMed Web of Science ®Google Scholar
• Farilla L Bulotta A Hirshberg B Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets Endocrinology 2003 144 12 5149 5158 12960095
   PubMed Web of Science ®Google Scholar
• Li YZ Hansotia T Yusta B Ris F Halban PA Drucker DJ Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis J Biol Chem 2003 278 1 471 478 12409292
   PubMed Web of Science ®Google Scholar
• Flint A Raben A Astrup A Holst JJ Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans J Clin Invest 1998 101 3 515 520 9449682
   PubMed Web of Science ®Google Scholar
• Baggio LL Huang Q Brown TJ Drucker DJ A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis Diabetes 2004 53 9 2492 2500 15331566
   PubMed Web of Science ®Google Scholar
• Nauck MA Kleine N Orskov C Holst JJ Willms B Creutzfeldt W Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients Diabetologia 1993 36 8 741 744 8405741
   PubMed Web of Science ®Google Scholar
• Amori RE Lau J Pittas AG Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 2007 298 2 194 206 17622601
   PubMed Web of Science ®Google Scholar
• Barnett AH New treatments in type 2 diabetes: a focus on the incretin-based therapies Clin Endocrinol (Oxf) 2009 70 3 343 353 18771570
   PubMed Web of Science ®Google Scholar
• Monami M Marchionni N Mannucci E Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials Eur J Endocrinol 2009 160 6 909 917 19318378
   PubMed Web of Science ®Google Scholar
• Norris SL Lee N Thakurta S Chan BK Exenatide efficacy and safety: a systematic review Diabet Med 2009 26 9 837 846 19719703
   PubMed Web of Science ®Google Scholar
• Shyangdan DS Royle PL Clar C Sharma P Waugh NR Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis BMC Endocr Disord 2010 10 20 21143938
   PubMed Web of Science ®Google Scholar
• NHS National Institute for Health and Clinical Excellence Clinical guidelines CG87: Type 2 diabetes – newer agents (partial CG66) (CG87) [homepage on the Internet] London, UK NHS National Institute for Health and Clinical Excellence 2009 Available from: http://www.nice.org.uk/cg87 Accessed March 25, 2013
   Google Scholar
• Buysschaert M Preumont V Oriot PR One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice Diabetes Metab 2010 36 5 381 388 20598606
   PubMed Web of Science ®Google Scholar
• Bergenstal RM Garrison LPJr Miller LA Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting Curr Med Res Opin 2011 27 12 2335 2342 22085180
   PubMed Web of Science ®Google Scholar
• Adam TC Westerterp-Plantenga MS Nutrient-stimulated GLP-1 release in normal-weight men and women Horm Metab Res 2005 37 2 111 117 15778929
   PubMed Web of Science ®Google Scholar
• Wallace TM Levy JC Matthews DR Use and abuse of HOMA modeling Diabetes Care 2004 27 6 1487 1495 15161807
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group Lancet 1998 352 9131 837 853 9742976
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) UK Prospective Diabetes Study (UKPDS) Group Lancet 1998 352 9131 854 865 9742977
   PubMed Web of Science ®Google Scholar
• Marchetti P Dotta F Lauro D Purrello F An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment Regul Pept 2008 146 1–3 4 11 17889380
   PubMedGoogle Scholar
• Charpentier G Vaur L Halimi S for DIAMETRE Predictors of response to glimepiride in patients with type 2 diabetes mellitus Diabetes Metab 2001 27 5 Pt 1 563 571 11694855
   PubMed Web of Science ®Google Scholar
• Pencek R Blickensderfer A Li Y Brunell SC Anderson PW Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index Postgrad Med 2012 124 4 21 32 22913891
   PubMed Web of Science ®Google Scholar
• Colditz GA Willett WC Stampfer MJ Weight as a risk factor for clinical diabetes in women Am J Epidemiol 1990 132 3 501 513 2389754
   PubMed Web of Science ®Google Scholar
• Seghieri G Tesi F Anichini R Gender modulates the relationship between body weight and plasma glucose in overweight or obese subjects Diabetes Res Clin Pract 2008 80 1 134 138 18077049
   PubMed Web of Science ®Google Scholar
• Wannamethee SG Papacosta O Lawlor DA Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women’s Heart Health Study Diabetologia 2012 55 1 80 87 21861177
   PubMed Web of Science ®Google Scholar